Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities

TY - JOUR

T1 - Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities

AU - Bauer, Alexander T

AU - Gorzelanny, Christian

AU - Gebhardt, Christoffer

AU - Pantel, Klaus

AU - Schneider, Stefan W

N1 - Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

PY - 2022/1

Y1 - 2022/1

N2 - Advances in understanding the molecular mechanisms of tumor progression have achieved impressive progress in the treatment of cancer and so-called immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Indeed, antibody-based drugs blocking immune escape of tumor cells by modulation of T cell responses are increasingly utilized for a wide range of tumor entities. Nonetheless, response rates remain limited, and the development of secondary resistance is a common problem. In addition, by increasing the immune response a variety of severe side effects are provoked. Next to autoimmune responses, activation of the complement system and skin toxicity, an increased incidence for thrombotic complications has been observed associated with an increased mortality rate. Based on this, it can be postulated that the interplay of coagulation with inflammation in the tumor microenvironment is relevant for each step in the tumor life cycle. This review focuses on the coagulation as central player fostering mechanisms associated with tumor progression. Thus, a better understanding of the molecular pathways involved in the complex interaction of circulating tumor cells, the plasmatic coagulation and immune cells may help to improve therapeutic concepts reducing mortality and morbidity associated with cancer.

AB - Advances in understanding the molecular mechanisms of tumor progression have achieved impressive progress in the treatment of cancer and so-called immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. Indeed, antibody-based drugs blocking immune escape of tumor cells by modulation of T cell responses are increasingly utilized for a wide range of tumor entities. Nonetheless, response rates remain limited, and the development of secondary resistance is a common problem. In addition, by increasing the immune response a variety of severe side effects are provoked. Next to autoimmune responses, activation of the complement system and skin toxicity, an increased incidence for thrombotic complications has been observed associated with an increased mortality rate. Based on this, it can be postulated that the interplay of coagulation with inflammation in the tumor microenvironment is relevant for each step in the tumor life cycle. This review focuses on the coagulation as central player fostering mechanisms associated with tumor progression. Thus, a better understanding of the molecular pathways involved in the complex interaction of circulating tumor cells, the plasmatic coagulation and immune cells may help to improve therapeutic concepts reducing mortality and morbidity associated with cancer.

KW - Anticoagulants/therapeutic use

KW - Blood Coagulation/drug effects

KW - Heparin, Low-Molecular-Weight/therapeutic use

KW - Humans

KW - Immune Checkpoint Inhibitors/therapeutic use

KW - Inflammation/blood

KW - Neoplasms/blood

KW - Thrombosis/blood

KW - Tumor Escape/drug effects

U2 - 10.1016/j.ctrv.2021.102322

DO - 10.1016/j.ctrv.2021.102322

M3 - SCORING: Review article

C2 - 34922151

VL - 102

JO - CANCER TREAT REV

JF - CANCER TREAT REV

SN - 0305-7372

M1 - 102322

ER -